Ebola – Tools for the new outbreak response

| December 20, 2018

article image
The Ebola outbreak in the Democratic Republic of Congo is a cause for concern. What can we learn from the 2014 outbreak in West Africa and what tools do we have to fight it. While the Ebola outbreak across West Africa only hit the headlines in 2014, when it caused a two-year epidemic, the disease was in fact first discovered in 1976 with outbreaks in Sudan and the DRC. 

Spotlight

UCLPartners

UCLPartners brings together an Academic Health Science Network (AHSN), Academic Health Science Centre (AHSC), NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC), Education Lead Provider and NIHR Clinical Research Network.

OTHER ARTICLES

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

How Pharma Companies Can Scale Up Their Knowledge Discovery with Semantic Similarity Search

Article | April 1, 2020

Pharma has deep roots in human history with centuries of folk pharmaceutical knowledge offering a hit-and-miss range of natural remedies. But the industry as we know it today actually emerged in the second half of the 19th century when the world’s first factory for the sole production of medicines was found. By the late 19th and early 20th century, some chemical companies had already begun using research labs to explore the medical applications for their products. Fast forward to today and the pharmaceutical sector is a global trillion-dollar industry. However, to ensure the safety and efficacy of drugs, the process of drug discovery and development is under extensive scrutiny and control on both national and global levels.

Read More

Pfizer Won’t Win the Coronavirus Pharma War

Article | April 1, 2020

Shares of Pfizer jumped more than 6% on Wednesday, after the company announced a plan to test some of its antiviral products as a potential treatment for the coronavirus from China. More than 35 million shares traded on the news — about 48% more than normal — as investors looked for any positive news from the pharma community after the recent selloff. So, does this mean that Pfizer stock is turning the corner?

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | April 1, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Spotlight

UCLPartners

UCLPartners brings together an Academic Health Science Network (AHSN), Academic Health Science Centre (AHSC), NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC), Education Lead Provider and NIHR Clinical Research Network.

Events